Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?

Liver International

Volumn 36, Issue 6, 2016, Pages 783-790

  D'Ambrosio, Roberta ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Interferon therapy; Predictors of liver cancer

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

ECHOGRAPHY; HEPATITIS C; HUMAN; LIVER CANCER; LIVER CIRRHOSIS; LIVER FIBROSIS; PRACTICE GUIDELINE; REMISSION; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE; CHRONIC HEPATITIS C; COMPLICATION; DISEASE EXACERBATION; ELASTOGRAPHY; EPIDEMIOLOGICAL MONITORING; HEPACIVIRUS; LIVER CELL CARCINOMA; LIVER TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUSTAINED VIROLOGIC RESPONSE; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; EPIDEMIOLOGICAL MONITORING; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUSTAINED VIROLOGIC RESPONSE;

EID: 84961784479     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13106     Document Type: Review

References (67)

1. Seef LB. Natural history of hepatitis C. Hepatology 1997; 26: 21S-8S.
2. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
3. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral and environmental factors. JAMA 2000; 284: 450-60.
4. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-10.
5. Gomez EV, Rodriguez YS, Bertot LC, et al. The natural history of compensated HCV-cirrhosis: a prospective long-term study. J Hepatol 2013; 58: 434-44.
6. Poynard T, Moussalli J, Munteanu M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013; 59: 675-83.
7. Wiese M, Fischer J, Lobermann M, et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology 2014; 59: 49-57.
8. Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced liver fibrosis. JAMA 2012; 308: 2584-93.
9. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015; 64: 495-503.
10. Hill AM, Saleem J, Heath KA, Simmons B. Effects of sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23, 309 patients with hepatitis C infection. Hepatology 2014; 60: 218A.
11. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206: 469-77.
12. Yoshida H, Tateishi R, Arakawa Y, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483-91.
13. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.
14. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.
15. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
16. Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with rediced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105-14.
17. Yoshida H, Tateishi R, Arakawa Y, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425-30.
18. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-7.
19. Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004; 101: 1616-22.
20. Iwasaki Y, Takaguchi K, Ikeda H, et al. Risk factors for hepatocellular carcinoma in hepatitis C patients with sustained virologic response to interferon therapy. Liver Int 2004; 24: 603-10.
21. Tokita H, Fukui H, Tanaka A, et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 2005; 20: 752-8.
22. Ikeda M, Fujiyama S, Tanaka M, et al. Risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005; 40: 148-56.
23. Tanaka A, Uegaki S, Kurihara H, et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007; 13: 5180-7.
24. Chang KC, Hung CH, Lu SN, et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother 2012; 67: 2766-72.
25. Huang CF, Yeh ML, Tsai PC, et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol 2014; 61: 67-74.
26. Van der Meer AJ, Feld JJ, Hofer H, et al. The risk for hepatocellular carcinoma among patients with chronic HCV infection and advanced hepatic fibrosis following sustained virological response. Hepatology 2013; 58: 280A.
27. Aleman S, Rahbin N, Weiland O, et al. A risk for hepatocellular carcinoma persistes long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013; 57: 230-6.
28. Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on the risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013; 57: 964-73.
29. Toyoda H, Tada T, Tsuji K, et al. Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: a multicenter study from Japan. Hepatol Res 2015. doi:10.1111/hepr.12613. [Epub ahead of print].
30. D'Ambrosio R, Della Corte C, Colombo M. Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy. Int J Mol Sci 2015; 16: 19698-712.
31. Bruix J, Sherman M. American Association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
32. European Association for the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012; 32(S1): 2-8.
33. European Association for the Study of the Liver; European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
34. European Association for the Study of the Liver. EASL practice guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
35. Ripoll C, Groszmann RJ, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009; 50: 923-8.
36. King LY, Canasto-Chibuque C, Johnson KB, et al. Gut 2015; 64: 1296-302.
37. Song PP, Xia JF, Inagaki Y, et al. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22: 262-74.
38. D'Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56: 532-43.
39. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
40. Regev A, Berho M, Jeffers LJ, et al. Sampling error and interobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-18.
41. D'Ambrosio R, Aghemo A, Fraquelli M, et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol 2013; 59: 251-6.
42. Lok AS, Everhart JE, Wright EC, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140: 840-9.
43. Terrault N, Zeuzem S, Di Bisceglie AM, et al. Treatment outcomes with 8, 12 and 24 week regimens of Ledipasvir/Sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study. Hepatology 2015; 62(SupplS1): 94A.
44. Afdhal N, Bacon B, Dieterich D, et al. Failure with all-oral DAA regimens: real-world experience from the TRIO network. Hepatology 2015; 62(SupplS1): 1390A-1A.
45. Foster GR, Irving WL, Cheung MCM, et al. Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016. doi:10.1016/j.jhep.2016.01.029. [Epub ahead of print].
46. Reichard O, Glaumann H, Frydén A, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783-7.
47. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
48. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
49. Arif A, Levine RA, Sanderson SO, et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 2003; 48: 1425-30.
50. Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004; 35: 107-12.
51. Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008; 27: 542-51.
52. George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-38.
53. Lau TY, Kleiner DE, Ghany MG, et al. 10-year follow-up after inteferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28: 1121-7.
54. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68, 276 biopsies. J Hepatol 1986; 2: 165-73.
55. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
56. Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44.
57. Guido M, Rugge M. Liver biopsy sampling in chronic viral hepatitis. Semin Liver Dis 2004; 24: 89-97.
58. Rousselet MC, Michalak S, Dupre F, et al. sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-64.
59. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-223.
60. Degasperi E, Grassi E, Fraquelli M, et al. Low accuracy of non-invasive tests for assessing residual cirrhosis in epatiti C patients with a sustained virological response. J Hepatol 2014; 60: S418.
61. D'Ambrosio R, Degasperi E, Fraquelli M, et al. Enhanced Liver Fibrosis (ELF) test does not predict residual cirrhosis after an SVR to hepatitis C treatment. J Hepatol 2015; 62: S610.
62. Tachi Y, Hirai T, Toyoda H, et al. Predictive ability of laboratory indices for liver fibrosis in patients with chronic hepatitis C after the eradication of hepatitis C virus. PLoS ONE 2015; 10: e0133515. doi:10.1371/journal.pone.0133515. eCollection 2015.
63. Fontana RJ, Bonkovsky HL, Naishadam D, et al. Serum fibrosis marker levels decrease after successful antivirl treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol 2009; 7: 219-26.
64. Yu ML, Lin SM, Chuang WL, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicenter study in Taiwan. Antivir Ther 2006; 11: 985-94.
65. Nagaoki Y, Aikata H, Nakano N, et al. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term, cohort study. J Gastroenterol Hepatol 2015. doi:10.1111/jgh.13236. [Epub ahead of print].
66. Toyoda H, Kumada T, Tada T, et al. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virological response for chronic hepatitis C virus infection. J Gastroenterol Hepatol 2015; 30: 1183-9.
67. Bruno S, Di Marco V, Iavarone M, et al. Survival of patients with HCV-related cirrhosis who achieved sustained virologic response equals those of general population. J Hepatol 2016. in press.